Investigating Phenotypic and Genotypic Resistance to Pyrazinamide Antibiotic in Multidrug-resistant (MDR) Mycobacterium Tuberculosis Isolates in Khuzestan Province from 2017 to 2022

Document Type : Original Article

Authors

1 Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

2 Infectious and Tropical Diseases Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

3 Department of Microbiology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

4 Department of Infectious Diseases, Imam Teaching Hospital, Ahvaz Jundishapur University of Medical Sciences Ahvaz, Iran.

10.32592/JSMJ.23.1.44

Abstract

Background and Objectives Pyrazinamide is one of the effective drugs for treating tuberculosis. Inclusion of this drug in the treatment regimen shortens the duration of tuberculosis treatment. The mutation in pncA gene causes loss of pyrazinamidase activity, the most important resistance mechanism in Mycobacterium tuberculosis isolates. Therefore, the purpose of this study is to investigate the phenotypic and genotypic resistance to pyrazinamide antibiotic in multidrug-resistant (MDR) Mycobacterium tuberculosis isolates in Khuzestan province between 2017 and 2022. Subjects and Methods This study was conducted on 40 isolates of Mycobacterium tuberculosis in Ahvaz TB Regional Laboratory. Drug sensitivity of the isolates was determined by the relative method in the antibiotic pyrazinamide in the isolates. Then, the frequency of pncA gene mutations related to pyrazinamide resistance in MDR isolates was determined using sequencing. Results According to the results of the drug sensitivity to rifampin and isoniazid antibiotics, there were 25 isolates, of which 16 strains were resistant to two drugs, namely isoniazid and rifampin (MDR-TB), and 9 were single-drug resistant isolates (8 isolates resistant to rifampin and 1 isolate resistant to Isoniazid). Of the 17 samples that had the pncA gene and were resistant to pyrazinamide, 13 had mutations in the pncA gene while 4 did not have any mutations. The most common mutation was a non-synonymous mutation in which the amino acid Val had changed to Phe. Conclusion According to the results of this study, there is a high frequency of resistance to pyrazinamide in MDR strains. Also, there is a high percentage of single-resistance mutations in the pncA gene, while there is lower prevalence of mutations in the panD and rpsA genes, which provide quick and accurate information about the sensitivity to pyrazinamide for MDR-TB and mono-resistant isolates. Therefore, the best method for detecting resistance to pyrazinamide is sequencing and whole pncA DNA sequence to confirm pyrazinamide resistance instead of the usual methods covering mutated hotspots.

Keywords

References

[1] World Health Organization (WHO). Global Tuberculosis Report 2022. Available at http://www.who.int/tb/en
[2] Zulqurnain M, Aijijiyah NP, Wati FA, Fadlan A, Azminah A, Santoso M. Synthesis, Mycobacterium tuberculosis H37Rv inhibitory activity, and molecular docking study of pyrazinamide analogs. Journal of Applied Pharmaceutical Science. 2023 Nov 4;13(11):170-7.
[3] Floto RA, Olivier KN, Saiman L, Daley CL, Herrmann JL, Nick JA, Noone PG, Bilton D, Corris P, Gibson RL, Hempstead SE. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. Thorax. 2016 Jan 1;71(Suppl 1):i1-22. [10.1136/thoraxjnl-2015-207360] [PMID]
[4] Sun Q, Li X, Perez LM, Shi W, Zhang Y, Sacchettini JC. The molecular basis of pyrazinamide activity on Mycobacterium tuberculosis PanD. Nature communications. 2020 Jan 17;11(1): 339. [10.1038/s41467-019-14238-3] [PMID]
[5] Tulyaprawat O, Chaiprasert A, Chongtrakool P, Suwannakarn K, Ngamskulrungroj P. Association of ubiA mutations and high-level of ethambutol resistance among Mycobacterium tuberculosis Thai clinical isolates. Tuberculosis. 2019 Jan 1; 114:42-6. [10.1038/s41467-019-14238-3 ] [PMID]
[6] Chen RH, Michael T, Kuhlin J, Schön T, Stocker S, Alffenaar JW. Is there a need to optimise pyrazinamide doses in patients with tuberculosis?: A Systematic Review. International Journal of Antimicrobial Agents. 2023 Jul 5:106914. [10.1016/j.ijan timicag.2023.106914] [PMID]
[7] Thiede JM, Dillon NA, Howe MD, Aflakpui R, Modlin SJ, Hoffner SE, Valafar F, Minato Y, Baughn AD. Pyrazinamide susceptibility is driven by activation of the SigE-dependent cell envelope stress response in mycobacterium tuberculosis. MBio. 2022 Feb 22;13(1):e00439-21. [10.1128/mbio.00439-21] [PMID]
[8] Bouz G, Slechta P, Jand’ourek O, Konecná K, Paterová P, Bárta P, Novák M, Kucera R, Dal NJ, Fenaroli F, Zemanová J. Hybridization Approach Toward Novel Antituberculars: Design, Synthesis, and Biological Evaluation of Compounds Combining Pyrazinamide and 4-Aminosalicylic Acid. ACS Infectious Diseases. 2022 Dec 28;9(1):79-96. [10.1021/acsinfecdis. 2c00433] [PMID]
[9] Haghdoost M, Nazmi PA, Osquee HO. Diagnostic value of serum IgG by Eliza to detecting Mycobacterium tuberculosis, Original Article. Journal of Research in Clinical Medicine. 2021 Jul 24;9(1):29.
[10] Narvaiz de Kantor I, Kim SJ, Frieden TR, Laszlo A, Luelmo F, Norval PY, Rieder HL, Valenzuela P, Weyer K. Laboratory services in tuberculosis control/writing committee: Isabel Narvaiz de Kantor...[et al.]. InLaboratory services in tuberculosis control/writing committee: Isabel Narvaiz de Kantor...[et al.] 1998.
[11] Winn Washington C, Allen SD, Janda WM, Koneman EW, Procop GW, Schreckenberger PC, Woods GL. Koneman's Color Atlas and Textbook of Diagnostic Microbiolgy. Lippincott, Williams & Wilkins; 2006.
[12] Khosravi AD, Goodarzi H, Alavi SM. Detection of genomic mutations in katG, inhA and rpoB genes of Mycobacterium tuberculosis isolates using polymerase chain reaction and
multiplex allele-specific polymerase chain reaction. Brazilian Journal of Infectious Diseases. 2012;16:57-62. [10.1016/ s1413-8670(12)70275-1] [PMID]
[13] Pál G. Introduction to Practical Biochemistry 2013 [Available from: http://elte.prompt.hu/sites/default/files/tananyagok/ IntroductionToPracticalBiochemistry/ch07.html.
[14] Heifets L, Sanchez T. New agar medium for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide. Journal of clinical microbiology. 2000 Apr 1;38(4):1498-501. [10.1128/JCM.38.4.1498-1501.2000] [PMID]
[15] Training Manual for Mycobacterium tuberculosis. Central TB division. https://tbcindia.gov.inn/view.php. 2009.
[16] Streicher EM, Maharaj K, York T, Van Heerden C, Barnard M, Diacon A, Mendel CM, Bosman ME, Hepple JA, Pym AS, Warren RM. Rapid sequencing of the Mycobacterium tuberculosis pncA gene for detection of pyrazinamide susceptibility. Journal of clinical microbiology. 2014 Nov;52(11):4056-7. [10.1128/ JCM.02438-14] [PMID] [17] Huang CK, Yu MC, Hung CS, Lin JC. Emerging insight of whole genome sequencing coupled with protein structure prediction into the pyrazinamide-resistance signature of Mycobacterium tuberculosis. International Journal of Antimicrobial Agents. 2024 Apr 1;63(4):107053. [10.1128/JCM.02438-14] [PMID]
[18] Wang Z, Tang Z, Heidari H, Molaeipour L, Ghanavati R, Kazemian H, Koohsar F, Kouhsari E. Global status of phenotypic pyrazinamide resistance in Mycobacterium tuberculosis clinical isolates: an updated systematic review and meta-analysis. Journal of Chemotherapy. 2023 Oct 3;35(7):583-95. [10.1080/1120009X.2023.2214473] [PMID]
[19] Pitaloka DA, Arfan A, Ramadhan DS, Chaidir L. Insights from the molecular mechanism of pyrazinamide to mutated pyrazinamidase linked to the pncA gene in clinical isolates of Mycobacterium tuberculosis. Journal of Biomolecular Structure and Dynamics. 2024 Jan 22;42(2):759-65. [10.1080/07391102. 2023.2195002] [PMID]
[20] Pitaloka DA, Arfan A, Ramadhan DS, Chaidir L. Insights from the molecular mechanism of pyrazinamide to mutated pyrazinamidase linked to the pncA gene in clinical isolates of Mycobacterium tuberculosis. Journal of Biomolecular Structure and Dynamics. 2024 Jan 22;42(2):759-65. [10.1080/ 07391102.2023.2195002] [PMID]
[21] Alame-Emane AK, Xu P, Pierre-Audigier C, Cadet-Daniel V, Shen X, Sraouia M, Siawaya JF, Takiff H, Gao Q, Gicquel B. Pyrazinamide resistance in Mycobacterium tuberculosis arises after rifampicin and fluoroquinolone resistance. The International Journal of Tuberculosis and Lung Disease. 2015 Jun 1;19(6):679-84. [10.5588/ijtld.14.0768] [PMID]
[22] Farazi A, Sofian M. Assessment of drug resistance in tuberculosis patients and the factors affecting it (2005-2010). Journal of Arak University of Medical Sciences. 2012 Apr 10;15(1):77-85.
[23] Kurbatova EV, Cavanaugh JS, Dalton T, S. Click E, Cegielski JP. Epidemiology of pyrazinamide-resistant tuberculosis in the United States, 1999–2009. Clinical infectious diseases. 2013 Oct 15;57(8):1081-93. [10.1093/cid/cit452] [PMID]
[24] Khoharo HK, Shaikh IA. Drug resistance patterns in pulmonary tuberculosis. JPMA-Journal of the Pakistan Medical Association. 2011 Mar 1;61(3):229. [PMID]
60
Hashemzadeh M, et al. Phenotypic and Genotypic Resistance to Pyrazinamide Antibiotic in Multidrug-resistant (MDR) Mycobacterium
Tuberculosis. JSMJ. 2024; 23(1):44-60
Jundishapur
Scientific Medical Journal
March & April 2024. Vol 23. No 1
[25] Che Y, Bo D, Lin X, Chen T, He T, Lin Y. Phenotypic and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates in Ningbo, China. BMC Infectious Diseases. 2021 Jun 25;21(1): 605. [10.1186/s12879-021-06306-1] [PMID]
[26] Pang Y, Zhu D, Zheng H, Shen J, Hu Y, Liu J, Zhao Y. Prevalence and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates from Southern China. BMC Infectious Diseases. 2017 Dec;17:1-8. [10.1186/s12879-017-2761-6] [PMID]
[27] Rahman A, Ferdous SS, Ahmed S, Rahman SM, Uddin MK, Pholwat S, Gratz J, Houpt E, Banu S. Pyrazinamide susceptibility and pncA mutation profiles of Mycobacterium tuberculosis among multidrug-resistant tuberculosis patients in Bangladesh. Antimicrobial Agents and Chemotherapy. 2017 Sep;61(9):10-128. [10.1128/AAC.00511-17] [PMID]
[28] Doustdar F, Khosravi AD, Farnia P. Mycobacterium tuberculosis genotypic diversity in pyrazinamide-resistant isolates of Iran. Microbial Drug Resistance. 2009 Dec 1;15(4):251-6. [10.1089/ mdr.2009.0066] [PMID]
[29] Khan MT, Malik SI, Ali S, Masood N, Nadeem T, Khan AS, Afzal MT. Pyrazinamide resistance and mutations in pncA among isolates of Mycobacterium tuberculosis from Khyber Pakhtunkhwa, Pakistan. BMC infectious diseases. 2019 Dec;19: 1-7. [10.1089/mdr.2009.0066] [PMID]
[30] Xia H, van Den Hof S, Cobelens F, Zhou Y, Zhao B, Wang S, Zhao Y. Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China. BMC Infectious Diseases. 2020 Dec;20:1-0. [10.1186/ s12879-020-4758-9] [PMID]
[31] Shi J, Su R, Zheng D, Zhu Y, Ma X, Wang S, Li H, Sun D. Pyrazinamide resistance and mutation patterns among multidrug-resistant Mycobacterium tuberculosis from Henan Province. Infection and drug resistance. 2020 Aug 20:2929-41. [10.2147/IDR.S260161 ] [PMID]
Jundishapur Scientific Medical Journal
Volume 23, Issue 1 - Serial Number 148
March and April 2024
Pages 44-60

Files

History

  • Receive Date: 08 January 2024
  • Revise Date: 05 March 2024
  • Accept Date: 06 March 2024

Share

How to cite

Statistics